S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
NASDAQ:IBB

iShares Biotechnology ETF (IBB) Price, Holdings, & News

$137.22
-0.57 (-0.41%)
(As of 03/28/2024 ET)
Today's Range
$137.13
$138.40
50-Day Range
$132.30
$140.89
52-Week Range
$111.83
$141.16
Volume
1.44 million shs
Average Volume
1.87 million shs
Market Capitalization
$7.74 billion
Assets Under Management
$7.66 billion
Dividend Yield
0.30%
Net Expense Ratio
0.44%
IBB stock logo

About iShares Biotechnology ETF (NASDAQ:IBB)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.

IBB Stock Price History

IBB ETF News Headlines

IBB: Let It Rest
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
3 Biotech ETFs Overdue for a Bounce
IBB Apr 2024 139.500 call
IBB Apr 2024 131.000 put
IBB Apr 2024 136.500 call
Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
Two Different Flavors of Biotech
See More Headlines
Receive IBB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iShares Biotechnology ETF and its competitors with MarketBeat's FREE daily newsletter.

Fund Details

Issuer
iShares
Fund Name
iShares Biotechnology ETF
Tax Classification
Regulated Investment Company
Current Symbol
NASDAQ:IBB
Inception Date
2/5/2001
Fund Manager
Diane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason
Web
N/A
Phone
N/A

Fund Focus

Asset Class
Equity
Benchmark
ICE Biotechnology Index (TR) (USD)
Category
Sector
Focus
Health Care
Development Level
Developed Markets
Region
North America
Number of Holdings
224

Fund Statistics

Assets Under Management
$7.66 billion
Average Daily Volume
$1.95 million
Discount/Premium
0.01%

Administrator, Advisor and Custodian

Administrator
JPMorgan Chase Bank, N.A.
Advisor
BlackRock Fund Advisors
Custodian
JPMorgan Chase Bank, N.A.
Distributor
BlackRock Investments, LLC
Transfer Agent
JPMorgan Chase Bank, N.A.
Trustee
N/A
Lead Market Maker
Latour Trading

Options

Optionable
Optionable
Options Volume
2,420
Put Options
1,230
Call Options
1,190
Short Interest
8,740,000 shs

Miscellaneous

Beta
0.73
Creation Unit
50,000
Creation Fee
$614.00
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

iShares Biotechnology ETF Expenses

TypeIBBHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFs
Management Fee0.44%0.57%0.54%0.48%0.51%
Other Expenses0.00%0.40%0.54%0.32%0.58%
Total Expense0.44%0.72%0.70%0.57%0.70%
Fee Waiver0.00%-0.53%-0.54%-0.20%-0.56%
Net Expense0.44%0.61%0.60%0.54%0.58%

iShares Biotechnology ETF (IBB) Holdings & Exposure

Key Executives

  • George G. C. Parker Ph.D.
    Independent Chairman of the Board of Trustees
  • Michael Arthur Latham
    President, Trustee
  • Jack Gee
    Chief Financial Officer, Treasurer
  • Geoffrey D. Flynn
    Chief Operating Officer, Executive Vice President

  • Bio & Compensation - 
  • Amy Schioldager
    Executive Vice President
  • Ira P. Shapiro
    Vice President, Chief Legal Officer
  • Matt Tucker
    Vice President

  • Bio & Compensation - 
  • Eilleen M. Clavere
    Secretary
  • Cecilia H. Herbert
    Independent Trustee
  • Charles A. Hurty
    Independent Trustee

IBB ETF - Frequently Asked Questions

How have IBB shares performed in 2024?

iShares Biotechnology ETF's stock was trading at $135.85 on January 1st, 2024. Since then, IBB stock has increased by 1.0% and is now trading at $137.22.
View the best growth stocks for 2024 here
.

How often does iShares Biotechnology ETF pay dividends? What is the dividend yield for iShares Biotechnology ETF?

iShares Biotechnology ETF announced a quarterly dividend on Wednesday, March 20th. Shareholders of record on Friday, March 22nd will be paid a dividend of $0.126 per share on Wednesday, March 27th. This represents a $0.50 dividend on an annualized basis and a yield of 0.37%. The ex-dividend date of this dividend is Thursday, March 21st.
Read our dividend analysis for IBB
.

What does IBB invest in?

iShares Biotechnology ETF is a equity fund issued by iShares. IBB focuses on health care investments and follows the ICE Biotechnology Index (TR) (USD). The fund's investments total to approximately $7.66 billion assets under management.

What stocks does iShares Biotechnology ETF hold?
What is the management fee for iShares Biotechnology ETF?

iShares Biotechnology ETF's management fee is 0.44% and has no other recorded expenses or fee waivers. The net expense ratio for IBB is 0.44%.

When did iShares Biotechnology ETF's stock split?

iShares Biotechnology ETF's stock split on the morning of Friday, December 1st 2017. The 3-1 split was announced on Tuesday, November 7th 2017. The newly issued shares were payable to shareholders after the closing bell on Thursday, November 30th 2017. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

What other stocks do shareholders of iShares Biotechnology ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iShares Biotechnology ETF investors own include NVIDIA (NVDA), Walt Disney (DIS), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Cisco Systems (CSCO), Micron Technology (MU), Bank of America (BAC), Johnson & Johnson (JNJ) and PayPal (PYPL).

Who are iShares Biotechnology ETF's major shareholders?

iShares Biotechnology ETF's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Citadel Advisors LLC (0.00%), Commerce Bank (1.31%), Wells Fargo & Company MN (1.20%), International Assets Investment Management LLC (1.01%), Barclays PLC (0.00%) and PNC Financial Services Group Inc. (0.70%).

How do I buy shares of iShares Biotechnology ETF?

Shares of IBB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IBB) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners